Views
17
Downloands
1
Amaç: Bu çalışmada, Kronik Hepatit B tanısı ile takipli hastaların Hepatit A seroprevalansının retrospektif olarak araştırılması ve duyarlı kişilerin aşılanması amaçlanmıştır. Gereç ve Yöntemler: Kasım 2018–Kasım 2019 tarihleri arasında hastanemiz enfeksiyon hastalıkları polikliniğine başvuran kronik hepatit B tanılı hastaların HAV Ab-IgG sonuçları değerlendirildi. HAVAb-IgG tetkiki, ARCHITECT i2000SR analizatöründe ARCHITECT® HAVAb-IgG test kiti ile Kemilüminesan Mikropartikül İmmünoassay (CMIA) yöntemi kullanılarak araştırılmıştır. Verilerin istatistiksel analiz Statistical Package for Social Scienses (SPSS) 21 (Inc. Chicago, Illinois, ABD) istatistik paket programıyla analiz edilmiştir. Bulgular: Kronik hepatit B tanısıyla izlenen 138 hasta değerlendirildi. Hastaların 27’sinde HAV Ab-IgG tetkiki yapılmamıştı. Çalışmaya 111 hasta dahil edildi. Hastaların 64’ü (%57,7) kadın, 47’si (%42,3) erkekti. Hastalar 15-84 yaş aralığına sahipti. Yaş ortalaması 48,01±11,86 yıl olarak tespit edildi. Anti-HAV IgG 105 (%94,6) hastada pozitif, 6 (%5,4) hastada negatifti. Anti-HAV IgG pozitif hastaların yaş ortalaması 49,25±11,31 tespit edildi. Anti-HAV IgG negatif olan hastaların 2’si (%33,3) kadın, 4’ü (%66,7) erkekti. Hastalar 15-36 yaş aralığına sahipti. Yaş ortalaması 26,16±5,16 yıl olarak tespit edildi. Sonuç: Kronik hepatit B virüs enfeksiyonu olan hastalarda hepatit A virüs seroprevalansı %94,6 olarak bulundu. HBV enfeksiyonu olan hastalarda HAV Ab-IgG tetkiki yapılmalı ve Anti-HAV IgG negatif olan hastalar aşılama programına alınmalıdır.
Purpose: This study aims to retrospective investigation of the seroprevalence of patients with chronic hepatitis B diagnosis and vaccination of sensitive people.Tools and Methods: The results of HAV Ab-IgG for patients with chronic hepatitis B diagnosed in the clinic of infectious diseases of our hospital between November 2018 and November 2019 were evaluated.The HAVAb-IgG examination was researched in the ARCHITECT i2000SR analyzer using the ARCHITECT HAVAb-IgG test kit and the chemical micropartitional micropartitional immunoassay (CMIA) method.®Statistical Package for Social Sciences (SPSS) 21Chicago, Illinois, USA) is analyzed by the statistical package program.Results: 138 patients with chronic hepatitis B diagnosed were evaluated. In 27 of the patients, HAV Ab-IgG was not examined. 111 patients were involved in the study. 64 of the patients (57.7 percent) were female and 47 (42.3 percent) male. Patients were between 15 and 84 years old. The average age was 48,01±11,86 years. Anti-HAV IgG 105 (94.6%) was positive in patients, 6 (5.4%) was negative in patients. The average age of anti-HAV IgG-positive patients was 49.25±11.31. 2 of the patients with anti-HAV IgG negative (33.3%) were female and 4 (66.7%) male. Patients were between 15 and 36 years old. The average age was 26.16±5.16 years. The result: in patients with chronic hepatitis B virus infection, the seroprevalence of hepatitis A virus was 94.6%. Patients with HBV infection should be examined HAV Ab-IgG and patients with anti-HAV IgG negative should be taken into the vaccination program.
Aim: The aim of this study was to retrospectively investigate Hepatitis A seroprevalence in patients with chronic hepatitis B and to vaccinate susceptible individuals. Material and Methods: Between November 2018 and November 2019, HAV Ab-IgG results of patients with chronic hepatitis B admitted to hospital infectious diseases outpatient clinic were evaluated. The HAVAb-IgG assay was investigated on the ARCHITECT i2000SR analyzer with the ARCHITECT® HAVAb-IgG assay using the Chemiluminescent Microparticle Immunoassay (CMIA) method. Statistical analysis of the data was analyzed using the Statistical Package for Social Sciences 21 statistical package program. Results: 138 patients with chronic hepatitis B were evaluated. HAV Ab-IgG was not performed in 27 patients. 111 patients were included in the study. 64 (57.7%) of the patients were female and 47 (42.3%) were male. The patients were between the ages of 15-84. The mean age was 48.01 ± 11.86 years. Anti-HAV IgG was positive in 105 (94.6%) patients and negative in 6 (5.4%) patients. The mean age of anti-HAV IgG positive patients was 49.25 ± 11.31 years. Of the patients with anti-HAV IgG negative, 2 (33.3%) were female and 4 (66.7%) were male. The patients were between 15-36 years old. The mean age was 26.16 ± 5.16 years. Discussion and Conclusion: Seroprevalence of hepatitis A virus was 94.6% in patients with chronic hepatitis B virus infection. HAV Ab-IgG should be tested in patients with HBV infection and patients who are anti-HAV IgG negative should be included in the vaccination program.
Field : Sağlık Bilimleri
Journal Type : Uluslararası
Article Detail 
Similar Articles
Download PDF
Journal Information
Listen Paper
Cite
Print This Page
Share
Mendeley
